Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7798 in adults with ileal Crohn's disease and ileostomy
NL-OMON59421Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azd7798 in Crohn's disease, sponsored by AstraZeneca. Primary endpoint: Safety and tolerability during induction. Started Mar 2025; status: completed.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59421.